CLUSTER filed Aug 14, 2026 at 16:54 ET
Five C-suite insiders at Edgewise Therapeutics sold a total of ~$401K in open-market shares on August 12, 2026, following the company's Q2 earnings miss and the transformative sevasemten sale to Servier. The sales are small relative to the $4.8B market cap (0.008%), but the cluster of all top executives selling on the same day after a major corporate pivot warrants attention. The non-cash grants and derivative exercises on the same date suggest these sales are likely liquidity-driven to cover tax obligations from vesting, not a bearish signal on the company's cardiovascular-focused future.